Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street

Philadelphia, PA 19107

(215) 955-2693
fax

Research and Clinical Interests
The main focus of Dr. Brody's laboratory is to find novel therapeutic strategies for pancreatic cancer patients.

Show Details

Publications

Most recent Peer-reviewed Publications

1. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
2. Molecular-based and alternative therapies for pancreatic cancer: Looking "out of the box"
3. HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells
4. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
5. A novel survival-based tissue microarray of pancreatic cancer validates muc1 and mesothelin as biomarkers
6. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient
7. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized
8. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
9. Loss of stromal Caveolin-1 expression in malignant melanoma metastases predicts poor survival
10. Subject Review: Pancreatic Ductal Adenocarcinoma in the Setting of Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: Case Report and Review of the Literature
11. The Past, Present, and Future of Biomarkers: A Need for Molecular Beacons for the Clinical Management of Pancreatic Cancer
12. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers
13. HuR's role in gemcitabine efficacy: An exception or opportunity?
14. pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs
15. CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: Implications for targeted gene therapy
16. CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancers
17. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients
18. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma
19. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence
20. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers

View All Publications